| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000237696 |
| P698 | PubMed publication ID | 9414141 |
| P2093 | author name string | Reunala T | |
| Brummer-Korvenkontio H | |||
| Mikkola J | |||
| Palosuo K | |||
| Sahi T | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Aedes | Q310911 | ||
| P304 | page(s) | 367-372 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | International Archives of Allergy and Immunology | Q2189251 |
| P1476 | title | Seasonal increase in human IgE and IgG4 antisaliva antibodies to Aedes mosquito bites | |
| P478 | volume | 114 |
| Q27468699 | Aedes aegypti D7 Saliva Protein Inhibits Dengue Virus Infection |
| Q35840659 | An insight into immunogenic salivary proteins of Anopheles gambiae in African children |
| Q34475692 | Anopheles salivary gland proteomes from major malaria vectors |
| Q35974756 | Biomarkers for exposure to sand flies bites as tools to aid control of leishmaniasis |
| Q35674577 | Canine Antibodies against Salivary Recombinant Proteins of Phlebotomus perniciosus: A Longitudinal Study in an Endemic Focus of Canine Leishmaniasis. |
| Q34875390 | Characterization of the antibody response to the saliva of Phlebotomus papatasi in people living in endemic areas of cutaneous leishmaniasis |
| Q43037970 | Comparison of cetirizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy |
| Q44166602 | Evaluation of the antibody response to Anopheles salivary antigens as a potential marker of risk of malaria |
| Q43230287 | Exposure to Phlebotomus papatasi and/or Leishmania major: possible etiologic link to Tunisian pemphigus |
| Q34483155 | First attempt to validate human IgG antibody response to Nterm-34kDa salivary peptide as biomarker for evaluating exposure to Aedes aegypti bites |
| Q28119695 | Human IgG Antibody Response to Aedes Nterm-34kDa Salivary Peptide, an Epidemiological Tool to Assess Vector Control in Chikungunya and Dengue Transmission Area |
| Q27489414 | Human IgG response to a salivary peptide, gSG6-P1, as a new immuno-epidemiological tool for evaluating low-level exposure to Anopheles bites |
| Q34328747 | IgG responses to Anopheles gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk |
| Q35916023 | IgG responses to the gSG6-P1 salivary peptide for evaluating human exposure to Anopheles bites in urban areas of Dakar region, Sénégal |
| Q60922267 | IgG1 and IgG4 antibodies against Aedes aegypti salivary proteins and risk for dengue infections |
| Q35156245 | IgG1 and IgG4 antibody responses to the Anopheles gambiae salivary protein gSG6 in the sympatric ethnic groups Mossi and Fulani in a malaria hyperhendemic area of Burkina Faso. |
| Q36423185 | Immune interactions between mosquitoes and their hosts |
| Q35398192 | Implication of haematophagous arthropod salivary proteins in host-vector interactions |
| Q35841520 | Kinetics of Anti-Phlebotomus perniciosus Saliva Antibodies in Experimentally Bitten Mice and Rabbits |
| Q34339785 | Kinetics of antibody response in BALB/c and C57BL/6 mice bitten by Phlebotomus papatasi |
| Q38245291 | Monitoring human tick-borne disease risk and tick bite exposure in Europe: available tools and promising future methods |
| Q35853310 | Mosquito salivary allergen Aed a 3: cloning, comprehensive molecular analysis, and clinical evaluation |
| Q34743782 | Mosquito salivary gland protein preservation in the field for immunological and biochemical analysis |
| Q37293213 | Natural Mosquito-Pathogen Hybrid IgG4 Antibodies in Vector-Borne Diseases: A Hypothesis |
| Q57137937 | New Immuno-Epidemiological Biomarker of Human Exposure to Aedes Vector Bites: From Concept to Applications |
| Q34110724 | Relationship between exposure to vector bites and antibody responses to mosquito salivary gland extracts |
| Q42979852 | Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy |
| Q28085738 | Salivary Biomarkers in the Control of Mosquito-Borne Diseases |
| Q35061198 | Use of anti-Aedes aegypti salivary extract antibody concentration to correlate risk of vector exposure and dengue transmission risk in Colombia |
Search more.